Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Let your healthcare provider know right away if you experience suicidal thoughts or ideation while taking bupropion
Promotes antioxidant levels*
Safety and efficacy depend on personalized health profiles, regular monitoring and medical oversight to mitigate risks and maximize outcomes
(28) The differences in findings between the Werkman et al
Metabolism shifts: Lower calorie intake can reduce your metabolic rate, which means your body generates less heat